Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.

Ye R, Kundrapu S, Gerson SL, Driscoll JJ, Beck R, Ali N, Landgren O, VanHeeckeren W, Luo G, Kroger N, Caimi P, De Lima M, Malek E.

Clin Lymphoma Myeloma Leuk. 2019 Jan 3. pii: S2152-2650(18)31189-3. doi: 10.1016/j.clml.2018.12.022. [Epub ahead of print]

PMID:
30878316
2.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]

PMID:
30858549
3.

Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.

Dosani T, Covut F, Pinto R, Kim BG, Ali N, Beck R, Maitta R, Downes K, Fox R, Reese J, de Lima M, Malek E.

Leuk Lymphoma. 2019 Mar 7:1-8. doi: 10.1080/10428194.2019.1573367. [Epub ahead of print]

PMID:
30845862
4.

FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials.

Sundaram S, Driscoll J, Fernandez-Ulloa M, de Lima M, Malek E.

Am J Nucl Med Mol Imaging. 2018 Dec 20;8(6):421-427. eCollection 2018.

5.

Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.

Covut F, Gupta D, Pinto R, Dambrosio N, El Jurdi N, Meyerson H, Ueda M, Kolk M, Creger R, Metheny L, Cooper BW, Caimi PF, Malek E, Otegbeye F, Lazarus HM, De Lima M, Tomlinson BK.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):73-82. doi: 10.1016/j.clml.2018.11.001. Epub 2018 Nov 12.

PMID:
30528848
6.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.

PMID:
30142419
7.
8.

Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia.

Ye R, Tomlinson B, de Lima M, Malek E.

Case Rep Hematol. 2018 May 13;2018:9807047. doi: 10.1155/2018/9807047. eCollection 2018.

9.

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.

Malek E, El-Jurdi N, Kröger N, de Lima M.

Front Oncol. 2017 Dec 11;7:287. doi: 10.3389/fonc.2017.00287. eCollection 2017. Review.

10.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
11.

Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.

Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash M.

Leuk Lymphoma. 2018 Aug;59(8):1905-1912. doi: 10.1080/10428194.2017.1408086. Epub 2018 Jan 2.

PMID:
29295650
12.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

13.

Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.

Tandra A, Covut F, Cooper B, Creger R, Brister L, McQuigg B, Caimi P, Malek E, Tomlinson B, Lazarus HM, Otegbeye F, Kolk M, de Lima M, Metheny L.

Leuk Lymphoma. 2018 Jul;59(7):1644-1651. doi: 10.1080/10428194.2017.1390234. Epub 2017 Dec 4.

PMID:
29199482
14.

Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates.

Malek E, Saygin C, Ye R, Covut F, Kim BG, Welge J, Meropol NJ, De Lima M, Driscoll JJ.

JCO Clin Cancer Inform. 2017 Nov;1:1-14. doi: 10.1200/CCI.17.00055.

15.
16.
17.

Resistant or Sensitive: Time is of the Essence.

Malek E, de Lima M, Caimi P.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1907-1908. doi: 10.1016/j.bbmt.2016.06.028. Epub 2016 Jul 5. No abstract available.

18.

Myeloid-derived suppressor cells: The green light for myeloma immune escape.

Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA.

Blood Rev. 2016 Sep;30(5):341-8. doi: 10.1016/j.blre.2016.04.002. Epub 2016 Apr 12. Review.

19.

Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.

Abdel Malek MA, Jagannathan S, Malek E, Sayed DM, Elgammal SA, Abd El-Azeem HG, Thabet NM, Driscoll JJ.

Oncotarget. 2015 Feb 20;6(5):3098-110.

20.

Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.

Jaganathan S, Malek E, Vallabhapurapu S, Vallabhapurapu S, Driscoll JJ.

Oncotarget. 2014 Dec 15;5(23):12358-70.

21.

Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.

Malek E, Jagannathan S, Driscoll JJ.

Oncotarget. 2014 Sep 30;5(18):8027-38. Review.

22.

MicroRNAs in brain metastases: potential role as diagnostics and therapeutics.

Alsidawi S, Malek E, Driscoll JJ.

Int J Mol Sci. 2014 Jun 11;15(6):10508-26. doi: 10.3390/ijms150610508. Review.

Supplemental Content

Loading ...
Support Center